SingHealth Duke-NUS Researchers Co-Authored a Book on Clinical Research Sample Sizes
Professor Tan Say Beng, Group Director of Research, SingHealth and Senior Associate
Dean, Duke-NUS, and Ms Tan Sze Huey, Principal Biostatistician, NCCS
co-authored the fourth and extended edition of “Sample Sizes for Clinical,
Laboratory and Epidemiology Studies”.
for medical researchers from all specialties and medical statisticians, the
book explains and explores the wide range of considerations necessary to assist
investigational teams when deriving an appropriate sample size for their study.
This edition includes content on Sample Size Software and the formulae and
numerical tables needed to design valid clinical studies.
Potential of Fetal Gene Therapy to Prevent Lethal Neurodegenerative Disease
A new study led by UCL, KK Women's and Children's Hospital (KKH) and National University Health System in Singapore have found that fetal gene therapy in mice can prevent a fatal neurodegenerative condition known as Gaucher disease, an irreversible, inherited genetic metabolic disorder which could lead to bone disease, seizure and brain damage. Given the promising results shown in mice, the Singapore team performed the test in non-human primates (NHP) at the early stages of pregnancy.
SGH Nurses Seconded to SCDF Help 995 Callers Save Lives
Since 2011, nurses-turned-operators at SCDF have helped increase CPR
performed by the public to 54%. The nurses guide 995 callers ~by telling them
what to do in an emergency. The nurses can also access the National Electronic
Health Record, and relay to paramedics information such as the patient's
medical history and drug allergies. Last year, SingHealth signed an agreement
with SCDF to increase the number of SingHealth nurses seconded to SCDF to 14.
National Cancer Centre Singapore (NCCS) and genomic medicine company Lucence Diagnostics will collaborate on a three-year study involving 300 patients to expland clinical database that classifies breast and gynaecological cancer mutations in Asian women across all ethnicities. This clinical database will be the first to focus on the Asian populations to improve genetic testing servies to provide more accurate diagnosis and enhance treatment selection.
Ground-breaking Discovery on Y90-RE Radiation Therapy by Singapore Team
A multidisciplinary team of researchers from National Cancer Centre Singapore (NCCS), Translational Immunology Institute (TII) and Singapore General Hospital (SGH) have discovered ground-breaking translational research that Yttrium-90 radioembolisation (Y90-RE), a form of radiation therapy increases anti-cancer immunity and improves tumour response in liver cancer patients. The team also reported the conclusion of a six-year long, 11-country Asia-Pacific phase-III clinical trial led by NCCS.
NHCS and SGH Doctors Find Ways to Improve Outcomes for Asian Heart Failure Patients
A first-ever prospective, multinational study of prescription medicine given to HRrEF patients revealed that doctors took into consideration that most medical studies were done in Western countries with Western patients, and therefore took a conservative approach in fear that Asian bodies may not suit the large dosage used for HFrEF treatment in Europe. This led to a prescription of only 1 out of 2 required medications. However, Prof Carolyn Lam, Principal Investigator of ASIAN-HF, and Senior Consultant, Department of Cardiology, Director of Clinical Trials, NHCS, revealed that it is safe to follow the standard practice in Europe because Western medical studies would have Asian representations as well.
First-ever Clinical Tool Developed to Identify Nose Cancer
NPC, also known as nasopharynx cancer, is the 7th most frequent cancer in males in Singapore. Scientists from National Cancer Centre Singapore (NCCS), in collaboration with Sun Yat-Sen University Cancer Centre (SYSUCC), have developed a first-ever validated clinical tool that helps clinicians identify relapse patients with aggressive NPC resistant to a repeat course of radiotherapy. "..Our prognostic model can also be used as a patient stratification or selection tool in future clinical trials for patients with locally recurrent NPC," Dr Tan Sze Huey, co-investigator and principal biostatistician at NCCS.